At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 6 enrolled
Drug / intervention
Dovitinibdrug
Likely dose
Dovitinib 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome
In Brief
A Phase 2 clinical trial evaluating Dovitinib for Von Hippel-Lindau Syndrome. Terminated early, enrolled 6 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
The goal of this clinical research study is to learn if dovitinib can safely be given to patients who have VHL with a measurable hemangioblastoma (tumor of the central nervous system). The effects of this drug on the disease will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVon Hippel-Lindau Syndrome
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2TerminatedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartNov 2012
Primary CompletionDec 2015
TodayJul 2026
First PostedDec 24, 2010
Enrollment StartNov 1, 2012
Primary CompletionDec 1, 2015
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 15.5 years ago
Interventions
Dovitinibdrug
500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).